New Drug Shows Promise for Bladder Cancer Treatment

An experimental treatment is making waves in the medical community as it demonstrates potential in tackling a tough-to-treat type of bladder cancer known as BCG-nonresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

BCG, or Bacillus Calmette-Guerin, has been the go-to immunotherapy for several early-stage bladder cancers. However, a new drug, TAR-200, has emerged from a clinical trial conducted by Janssen Research & Development LLC, a part of Johnson & Johnson. This offers what might be a less invasive option than the full removal of the bladder, also known as cystectomy.

The disease is particularly alarming, as it ranks among the top ten causes of death globally with increasing infection rates.

TAR-200 is a small device that releases medication directly into the bladder through a simple outpatient procedure that doesn’t require general anesthesia. After being placed, it slowly dispenses the chemotherapy drug gemcitabine over several weeks.

“For a long time, patients facing this type of cancer had few options available to them. This new treatment may be the most effective reported yet for the most prevalent form of bladder cancer,” said Dr. Thea Dhaneshmand, the study’s lead investigator and director of Urologic Oncology at Keck Medicine USC, in a press announcement.

Bladder cancer ranks as the fourth most common cancer in men and the 11th in women. According to the Urology Care Foundation, non-muscle-invasive bladder cancer starts in the bladder’s lining.

Dr. Dhaneshmand added, “This clinical trial could represent a significant step forward in treating certain types of bladder cancer, possibly leading to better outcomes and even saving lives.”

High-risk NMIBC tends to recur after treatment, which was the focus of this study—mainly exploring options for patients whose cancer returned despite standard treatments.

Traditionally, treatment has involved surgical removal of the bladder and nearby tissues, a procedure that carries its own health risks and can significantly affect life quality. With this new approach, some patients might avoid surgery altogether.

In the clinical trial, all participants were patients with high-risk NMIBC who did not respond to BCG. The study tested various groups with different drug combinations. For one group, patients received TAR-200 every three weeks for about six months, followed by maintenance therapy every three months for up to two years.

Of the 85 patients in this specific group, an impressive 82.4% showed no detectable cancer signs after treatment. By the one-year mark, 52.9% remained cancer-free, many staying that way for over two years without further treatments.

Moreover, for another group with less aggressive early-stage bladder cancer, an 85.3% disease-free rate at six months and 81.1% at nine months were reported, with 94% able to retain their bladders.

The results of this trial were published earlier this year in the Journal of Clinical Oncology.

However, researchers were quick to note that the current data is still mid-term. Longer, larger-scale trials and regulatory assessments are required before this treatment can be widely adopted.

“There wasn’t a conventional comparison group in this study, so we can’t definitively say how TAR-200 stacks up against other options,” the researchers acknowledged.

It’s important to realize that the study’s patients represent a specific group—those resistant to BCG and suitable for bladder preservation—so they’re not reflective of all bladder cancer cases.

Additionally, the follow-up duration is still relatively brief, and the patient pool isn’t large enough, leaving questions about how long the positive effects will last and how this treatment will apply to a broader range of patients.